Analysing the reports on counterfeit and sub-standard medicines
- At: 2005 FIP Congress in Cairo (Egypt)
- Type: Presentation
- By: NICHOLSON, Jane (Industrial Pharmacy Section, Regulatory Affairs, Slough, United Kingdom)
When companies acquire a sample of a product that could potentially be counterfeit from either pharmacists, consumers or other party, analysts at the manufacturers’ laboratories should run tests to examine the components of the medicine and determine whether it is a fake. If it is, this should be reported to the National Government Authorities.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.